Lupin gets Marketing Approval for Cefpodoxime Proxetil in France

Lupin Ltd on March 13, 2007 has announced that, together with it's French Regulatory agent Venipharm, it has received the Marketing Approval for generic Cefpodoxime Proxetil 100mg tablets in France. Cefpodoxime Proxetil is a cephalosporin antibiotic used to treat a variety of bacterial infections.

The Company's Cefpodoxime Proxetil tablets would be the generic equivalent of Sanofi-Aventis's Orelox tablets. Sales of Orelox tablets in France are close to Euro 75m as per IMS and the patent expiry is August 2007. The French market is the biggest European market for Cefpodoxime Proxetil.

"This is the first generic approval in France for Cefpodixime Proxetil and Lupin's first significant approval in Europe. We will work with our partners to ensure launch of this generic upon patent expiry. We expect a number of other such approvals in Europe in the coming months," said Dr. Kamal Sharma, Managing Director, of the Company.

Source : Equity Bulls

Keywords